• Publications
  • Influence
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
CONTEXT Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors (PDE5-Is) have showed significant improvements in both lower urinary tract symptoms (LUTS) and erectileExpand
  • 232
  • 12
Metabolic syndrome and benign prostatic enlargement: a systematic review and meta‐analysis
To summarise and meta‐analyse current literature on metabolic syndrome (MetS) and benign prostatic enlargement (BPE), focusing on all the components of MetS and their relationship with prostateExpand
  • 145
  • 11
  • PDF
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Metabolic syndrome (MetS) and benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) are often associated. One of their common denominators is hypogonadism. However, testosteroneExpand
  • 143
  • 9
  • PDF
Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells.
Progression of benign prostatic hyperplasia (BPH) involves chronic inflammation and immune dysregulation. Preclinical studies have demonstrated that prostate inflammation and tissue remodeling areExpand
  • 99
  • 9
  • PDF
Sperm recovery and ICSI outcomes in Klinefelter syndrome: a systematic review and meta-analysis
BACKGROUND Specific factors underlying successful surgical sperm retrieval rates (SRR) or pregnancy rates (PR) after testicular sperm extraction (TESE) in adult patients with Klinefelter syndromeExpand
  • 84
  • 9
  • PDF
Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction.
INTRODUCTION A limiting step in the evaluation of female sexual dysfunction (FSD) is the availability of a rapid screening procedure. Often, practitioners avoid investigating sexual symptoms due toExpand
  • 129
  • 8
Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats.
INTRODUCTION In humans, prostate phosphodiesterase type 5 inhibitors (PDE5) expression was prominently localized in the endothelial and smooth muscle cells of the vascular bed, suggesting a possibleExpand
  • 124
  • 7
THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study.
OBJECTIVE The role of testosterone (T) in regulating body composition is conflicting. Thus, our goal is to meta-analyse the effects of T supplementation (TS) on body composition and metabolicExpand
  • 104
  • 6
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia
CRD summary This review concluded that phosphodiesterase type 5 inhibitors were effective and well tolerated alone or combined with alpha-blockers in men with lower urinary tract symptoms associatedExpand
  • 82
  • 5
Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract.
INTRODUCTION Phosphodiesterase type 5 (PDE5) inhibitors ameliorate low urinary tract (LUT) symptoms in men with ED and symptomatic benign prostatic hyperplasia (BPH). PDE5 is highly expressed in ratExpand
  • 119
  • 5